Omalizumab alleviates pruritus in myeloproliferative neoplasms

Anna Ravn Landtblom; Johanna Ungerstedt; Anette Hedlund; Magnus Tobiasson; Stefan Deneberg; Martin Jädersten

doi:10.3324/haematol.2022.281639

Omalizumab alleviates pruritus in myeloproliferative neoplasms

Haematologica. 2023 Jul 1;108(7):1968-1971. doi: 10.3324/haematol.2022.281639.

Authors

Anna Ravn Landtblom¹, Johanna Ungerstedt², Anette Hedlund³, Magnus Tobiasson², Stefan Deneberg², Martin Jädersten⁴

Affiliations

¹ Department of Medicine, Solna, Karolinska Institutet, Stockholm, Sweden; Department of Hematology, Karolinska University Hospital, Stockholm.
² Department of Hematology, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm.
³ Department of Hematology, Karolinska University Hospital, Stockholm.
⁴ Department of Hematology, Karolinska University Hospital, Stockholm, Sweden; Center for Hematology and Regenerative Medicine, Department of Medicine, Huddinge, Karolinska Institutet, Stockholm. martin.jadersten@regionstockholm.se.

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Myeloproliferative Disorders* / complications
Myeloproliferative Disorders* / drug therapy
Myeloproliferative Disorders* / genetics
Neoplasms*
Omalizumab / therapeutic use
Pruritus / drug therapy
Pruritus / etiology

Substances

Omalizumab

Grants and funding

Funding: This work was funded by Blodcancerfonden, The Cancer Research Foundations of Radiumhemmet, CIMED, Karolinska Institutet Translational Seed Grant and the Nordic Cancer Union.